Restorative cell therapy for Parkinson's disease: A quest for the perfect cell

Seminars in Cell and Developmental Biology

Volumn 18, Issue 6, 2007, Pages 859-869

  Hall, Vanessa J ^a   Li, Jia Yi ^a   Brundin, Patrik ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Adult stem cells; Cell transplantation; Embryonic stem cells; Neural stem cells; Parkinson's disease; Restorative medicine; Review; Ventral mesencephalon

Indexed keywords

LEVODOPA;

CELL THERAPY; CELL TRANSPLANTATION; CELL TYPE; CLINICAL RESEARCH; DEGENERATIVE DISEASE; DNA MODIFICATION; DONOR; DOPAMINERGIC NERVE CELL; DYSKINESIA; EMBRYO CELL; EMBRYONIC STEM CELL; FETUS CELL; HUMAN; MENTAL DISEASE; MESENCEPHALON; MOTOR DYSFUNCTION; NEURAL STEM CELL; PARKINSON DISEASE; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION;

EID: 36249002320     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcdb.2007.09.004     Document Type: Review

References (107)

1. Alvarez-Dolado M., Pardal R., Garcia-Verdugo J.M., Fike J.R., Lee H.O., Pfeffer K., et al. Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature 425 (2003) 968-973
2. Andersson E., Tryggvason U., Deng Q., Friling S., Alekseenko Z., Robert B., et al. Identification of intrinsic determinants of midbrain dopamine neurons. Cell 124 (2006) 393-405
3. Andersson E.K., Irvin D.K., Ahlsio J., and Parmar M. Ngn2 and Nurr1 act in synergy to induce midbrain dopaminergic neurons from expanded neural stem and progenitor cells. Exp Cell Res 313 (2007) 1172-1180
4. Arai R., Karasawa N., and Nagatsu I. Aromatic L-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence study. Brain Res 706 (1996) 177-179
5. Baker M. Flawed data in multipotent stem cell study. Nat Rep Stem Cells (2007)
6. Barberi T., Klivenyi P., Calingasan N.Y., Lee H., Kawamata H., Loonam K., et al. Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nat Biotechnol 21 (2003) 1200-1207
7. Ben-Hur T., Idelson M., Khaner H., Pera M., Reinhartz E., Itzik A., et al. Transplantation of human embryonic stem cell-derived neural progenitors improves behavioral deficit in Parkinsonian rats. Stem Cells 22 (2004) 1246-1255
8. Bjorklund A., Dunnett S.B., Brundin P., Stoessl A.J., Freed C.R., Breeze R.E., et al. Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol 2 (2003) 437-445
9. Bjorklund A., and Stenevi U. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res 177 (1979) 555-560
10. Brederlau A., Correia A.S., Anisimov S.V., Elmi M., Paul G., Roybon L., et al. Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: effect of in vitro differentiation on graft survival and teratoma formation. Stem Cells 24 (2006) 1433-1440
11. Brevig T., Holgersson J., and Widner H. Xenotransplantation for CNS repair: immunological barriers and strategies to overcome them. Trends Neurosci 23 (2000) 337-344
12. Brundin P., and Bjorklund A. Survival, growth and function of dopaminergic neurons grafted to the brain. Prog Brain Res 71 (1987) 293-308
13. Brundin P., Nilsson O.G., Strecker R.E., Lindvall O., Astedt B., and Bjorklund A. Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson's disease. Exp Brain Res 65 (1986) 235-240
14. Brundin P., Pogarell O., Hagell P., Piccini P., Widner H., Schrag A., et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 123 Pt 7 (2000) 1380-1390
15. Caldwell M.A., and Svendsen C.N. Heparin, but not other proteoglycans potentiates the mitogenic effects of FGF-2 on mesencephalic precursor cells. Exp Neurol 152 (1998) 1-10
16. Carvey P.M., Ling Z.D., Sortwell C.E., Pitzer M.R., McGuire S.O., Storch A., et al. A clonal line of mesencephalic progenitor cells converted to dopamine neurons by hematopoietic cytokines: a source of cells for transplantation in Parkinson's disease. Exp Neurol 171 (2001) 98-108
17. Cho Y.H., Kim D.S., Kim P.G., Hwang Y.S., Cho M.S., Moon S.Y., et al. Dopamine neurons derived from embryonic stem cells efficiently induce behavioral recovery in a Parkinsonian rat model. Biochem Biophys Res Commun 341 (2006) 6-12
18. Christophersen N.S., and Brundin P. Large stem cell grafts could lead to erroneous interpretations of behavioral results?. Nat Med 13 (2007) 118 [author reply 118-119]
19. Conti L., Reitano E., and Cattaneo E. Neural stem cell systems: diversities and properties after transplantation in animal models of diseases. Brain Pathol 16 (2006) 143-154
20. D'Ippolito G., Diabira S., Howard G.A., Menei P., Roos B.A., and Schiller P.C. Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J Cell Sci 117 (2004) 2971-2981
21. D'Ippolito G., Howard G.A., Roos B.A., and Schiller P.C. Isolation and characterization of marrow-isolated adult multilineage inducible (MIAMI) cells. Exp Hematol 34 (2006) 1608-1610
22. Duan W.M., Brundin P., and Widner H. Addition of allogeneic spleen cells causes rejection of intrastriatal embryonic mesencephalic allografts in the rat. Neuroscience 77 (1997) 599-609
23. Duan W.M., Cameron R.M., Brundin P., and Widner H. Rat intrastriatal neural allografts challenged with skin allografts at different time points. Exp Neurol 148 (1997) 334-347
24. Fahn S. Levodopa in the treatment of Parkinson's disease. J Neural Transm Suppl (2006) 1-15
25. Freed C.R., Breeze R.E., Rosenberg N.L., Schneck S.A., Kriek E., Qi J.X., et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med 327 (1992) 1549-1555
26. Freed C.R., Breeze R.E., Rosenberg N.L., Schneck S.A., Wells T.H., Barrett J.N., et al. Transplantation of human fetal dopamine cells for Parkinson's disease. Results at 1 year. Arch Neurol 47 (1990) 505-512
27. Freed C.R., Breeze R.E., Rosenberg N.L., Schneck S.A., Wells T.H., Barrett J.N., et al. Therapeutic effects of human fetal dopamine cells transplanted in a patient with Parkinson's disease. Prog Brain Res 82 (1990) 715-721
28. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344 (2001) 710-719
29. Freeman T.B., and Brundin P. Important aspects of surgical methodology for transplantation in parkinson's disease. In: Brundin P., and Olanow C.W. (Eds). Restorative therapies in Parkinson's disease (2006), Springer, New York 365
30. Hagell P., and Brundin P. Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. J Neuropathol Exp Neurol 60 (2001) 741-752
31. Hagell P., Piccini P., Bjorklund A., Brundin P., Rehncrona S., Widner H., et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci 5 (2002) 627-628
32. Hauser R.A., and Zesiewicz T.A. Advances in the pharmacologic management of early Parkinson disease. Neurologist 13 (2007) 126-132
33. Hokfelt T., Fuxe K., and Goldstein M. Immunohistochemical localization of aromatic L-amino acid decarboxylase (DOPA decarboxylase) in central dopamine and 5-hydroxytryptamine nerve cell bodies of the rat. Brain Res 53 (1973) 175-180
34. Iacovitti L., Donaldson A.E., Marshall C.E., Suon S., and Yang M. A protocol for the differentiation of human embryonic stem cells into dopaminergic neurons using only chemically defined human additives: studies in vitro and in vivo. Brain Res 1127 (2007) 19-25
35. Inden M., Kim D., Gu Y., Kitamura Y., Kondo J., Tsuchiya D., et al. Pharmacological characteristics of rotational behavior in hemiparkinsonian rats transplanted with mouse embryonic stem cell-derived neurons. J Pharmacol Sci 96 (2004) 53-64
36. Inden M., Kim D.H., Qi M., Kitamura Y., Yanagisawa D., Nishimura K., et al. Transplantation of mouse embryonic stem cell-derived neurons into the striatum, subthalamic nucleus and substantia nigra, and behavioral recovery in hemiparkinsonian rats. Neurosci Lett 387 (2005) 151-156
37. Jensen J.B., and Parmar M. Strengths and limitations of the neurosphere culture system. Mol Neurobiol 34 (2006) 153-161
38. Jiang Y., Jahagirdar B.N., Reinhardt R.L., Schwartz R.E., Keene C.D., Ortiz-Gonzalez X.R., et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418 (2002) 41-49
39. Jiang Y., Vaessen B., Lenvik T., Blackstad M., Reyes M., and Verfaillie C.M. Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp Hematol 30 (2002) 896-904
40. Kawasaki H., Mizuseki K., Nishikawa S., Kaneko S., Kuwana Y., Nakanishi S., et al. Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron 28 (2000) 31-40
41. Kim H.J., Sugimori M., Nakafuku M., and Svendsen C.N. Control of neurogenesis and tyrosine hydroxylase expression in neural progenitor cells through bHLH proteins and Nurr1. Exp Neurol 203 (2007) 394-405
42. Kim H.T., Kim I.S., Lee I.S., Lee J.P., Snyder E.Y., and Park K.I. Human neurospheres derived from the fetal central nervous system are regionally and temporally specified but are not committed. Exp Neurol 199 (2006) 222-235
43. Kim J.H., Auerbach J.M., Rodriguez-Gomez J.A., Velasco I., Gavin D., Lumelsky N., et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 418 (2002) 50-56
44. Kim J.Y., Koh H.C., Lee J.Y., Chang M.Y., Kim Y.C., Chung H.Y., et al. Dopaminergic neuronal differentiation from rat embryonic neural precursors by Nurr1 overexpression. J Neurochem 85 (2003) 1443-1454
45. Kim T.E., Lee H.S., Lee Y.B., Hong S.H., Lee Y.S., Ichinose H., et al. Sonic hedgehog and FGF8 collaborate to induce dopaminergic phenotypes in the Nurr1-overexpressing neural stem cell. Biochem Biophys Res Commun 305 (2003) 1040-1048
46. Kitchens D.L., Snyder E.Y., and Gottlieb D.I. FGF and EGF are mitogens for immortalized neural progenitors. J Neurobiol 25 (1994) 797-807
47. Koller W.C., and Rueda M.G. Mechanism of action of dopaminergic agents in Parkinson's disease. Neurology 50 (1998) S11-S14 [discussion S44-18]
48. Kordower J.H., Freeman T.B., Snow B.J., Vingerhoets F.J., Mufson E.J., Sanberg P.R., et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 332 (1995) 1118-1124
49. Kordower J.H., Styren S., Clarke M., Dekosky S.T., Olanow C.W., and Freeman T.B. Fetal grafting for Parkinson's disease: Expression of immune markers in two patients with functional fetal nigral implants. Cell Transplant 6 (1997) 213-219
50. Lee S.H., Lumelsky N., Studer L., Auerbach J.M., and McKay R.D. Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat Biotechnol 18 (2000) 675-679
51. Liew C.G., Draper J.S., Walsh J., Moore H., and Andrews P.W. Transient and stable transgene expression in human embryonic stem cells. Stem Cells 25 (2007) 1521-1528
52. Lindvall O., Brundin P., Widner H., Rehncrona S., Gustavii B., Frackowiak R., et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 247 (1990) 574-577
53. Lindvall O., Rehncrona S., Brundin P., Gustavii B., Astedt B., Widner H., et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch Neurol 46 (1989) 615-631
54. Lindvall O., Rehncrona S., Gustavii B., Brundin P., Astedt B., Widner H., et al. Fetal dopamine-rich mesencephalic grafts in Parkinson's disease. Lancet 2 (1988) 1483-1484
55. Lindvall O., Sawle G., Widner H., Rothwell J.C., Bjorklund A., Brooks D., et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 35 (1994) 172-180
56. Ling Z.D., Potter E.D., Lipton J.W., and Carvey P.M. Differentiation of mesencephalic progenitor cells into dopaminergic neurons by cytokines. Exp Neurol 149 (1998) 411-423
57. Liu W.G., Lu G.Q., Li B., and Chen S.D. Dopaminergic neuroprotection by neurturin-expressing c17.2 neural stem cells in a rat model of Parkinson's disease. Parkinsonism Relat Disord 13 (2007) 77-88
58. Madrazo I., Franco-Bourland R., Ostrosky-Solis F., Aguilera M., Cuevas C., Alvarez F., et al. Neural transplantation (auto-adrenal, fetal nigral and fetal adrenal) in Parkinson's disease: the Mexican experience. Prog Brain Res 82 (1990) 593-602
59. Madrazo I., Leon V., Torres C., Aguilera M.C., Varela G., Alvarez F., et al. Transplantation of fetal substantia nigra and adrenal medulla to the caudate nucleus in two patients with Parkinson's disease. N Engl J Med 318 (1988) 51
60. McKay R. Stem cells in the central nervous system. Science 276 (1997) 66-71
61. Mendez I., Sanchez-Pernaute R., Cooper O., Vinuela A., Ferrari D., Bjorklund L., et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 128 (2005) 1498-1510
62. Menendez P., Bueno C., Wang L., and Bhatia M. Human embryonic stem cells: potential tool for achieving immunotolerance?. Stem Cell Rev 1 (2005) 151-158
63. Morizane A., Takahashi J., Shinoyama M., Ideguchi M., Takagi Y., Fukuda H., et al. Generation of graftable dopaminergic neuron progenitors from mouse ES cells by a combination of coculture and neurosphere methods. J Neurosci Res 83 (2006) 1015-1027
64. Moses D., Teper Y., Gantois I., Finkelstein D.I., Horne M.K., and Drago J. Murine embryonic EGF-responsive ventral mesencephalic neurospheres display distinct regional specification and promote survival of dopaminergic neurons. Exp Neurol 199 (2006) 209-221
65. Nern C., and Momma S. The realized niche of adult neural stem cells. Stem Cell Rev 2 (2006) 233-240
66. Olanow C.W. Parkinson's disease: Clinical crossroads. JAMA 275 (1996) 716-722
67. Olanow C.W., and Fahn S. Fetal nigral transplantation as a therapy for parkinson's disease. In: Brundin P., and Olanow C.W. (Eds). Restorative therapies in Parkinson's disease (2006), Springer, New York 365
68. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54 (2003) 403-414
69. Perlow M.J., Freed W.J., Hoffer B.J., Seiger A., Olson L., and Wyatt R.J. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 204 (1979) 643-647
70. Perrier A.L., Tabar V., Barberi T., Rubio M.E., Bruses J., Topf N., et al. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci USA 101 (2004) 12543-12548
71. Peschanski M., Defer G., N'Guyen J.P., Ricolfi F., Monfort J.C., Remy P., et al. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 117 Pt 3 (1994) 487-499
72. Piccini P., Lindvall O., Bjorklund A., Brundin P., Hagell P., Ceravolo R., et al. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol 48 (2000) 689-695
73. Potter E.D., Ling Z.D., and Carvey P.M. Cytokine-induced conversion of mesencephalic-derived progenitor cells into dopamine neurons. Cell Tissue Res 296 (1999) 235-246
74. Raedt R., Pinxteren J., Van Dycke A., Waeytens A., Craeye D., Timmermans F., et al. Differentiation assays of bone marrow-derived Multipotent Adult Progenitor Cell (MAPC)-like cells towards neural cells cannot depend on morphology and a limited set of neural markers. Exp Neurol 203 (2007) 542-554
75. Redmond Jr. D.E., Bjugstad K.B., Teng Y.D., Ourednik V., Ourednik J., Wakeman D.R., et al. From the Cover: Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cells. Proc Natl Acad Sci USA 104 (2007) 12175-12180
76. Riaz S.S., and Bradford H.F. Factors involved in the determination of the neurotransmitter phenotype of developing neurons of the CNS: applications in cell replacement treatment for Parkinson's disease. Prog Neurobiol 76 (2005) 257-278
77. Riaz S.S., Jauniaux E., Stern G.M., and Bradford H.F. The controlled conversion of human neural progenitor cells derived from foetal ventral mesencephalon into dopaminergic neurons in vitro. Brain Res Dev Brain Res 136 (2002) 27-34
78. Richardson R.M., Fillmore H.L., Holloway K.L., and Broaddus W.C. Progress in cerebral transplantation of expanded neuronal stem cells. J Neurosurg 100 (2004) 659-671
79. Rizvi A.Z., Swain J.R., Davies P.S., Bailey A.S., Decker A.D., Willenbring H., et al. Bone marrow-derived cells fuse with normal and transformed intestinal stem cells. Proc Natl Acad Sci USA 103 (2006) 6321-6325
80. Rodriguez-Gomez J.A., Lu J.Q., Velasco I., Rivera S., Zoghbi S.S., Liow J.S., et al. Persistent dopamine functions of neurons derived from embryonic stem cells in a rodent model of Parkinson disease. Stem Cells 25 (2007) 918-928
81. Roy N.S., Cleren C., Singh S.K., Yang L., Beal M.F., and Goldman S.A. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med 12 (2006) 1259-1268
82. Roybon L., Brundin P., and Li J.Y. Stromal cell-derived inducing activity does not promote dopaminergic differentiation, but enhances differentiation and proliferation of neural stem cell-derived astrocytes. Exp Neurol 196 (2005) 373-380
83. Roybon L., Ma Z., Asztely F., Fosum A., Jacobsen S.E., Brundin P., et al. Failure of transdifferentiation of adult hematopoietic stem cells into neurons. Stem Cells 24 (2006) 1594-1604
84. Sanberg P.R. Neural stem cells for Parkinson's disease: to protect and repair. Proc Natl Acad Sci USA 104 (2007) 11869-11870
85. Sanchez-Pernaute R., Studer L., Bankiewicz K.S., Major E.O., and McKay R.D. In vitro generation and transplantation of precursor-derived human dopamine neurons. J Neurosci Res 65 (2001) 284-288
86. Satoh J., and Kuroda Y. The constitutive and inducible expression of Nurr1, a key regulator of dopaminergic neuronal differentiation, in human neural and non-neural cell lines. Neuropathology 22 (2002) 219-232
87. Sawamoto K., Nakao N., Kakishita K., Ogawa Y., Toyama Y., Yamamoto A., et al. Generation of dopaminergic neurons in the adult brain from mesencephalic precursor cells labeled with a nestin-GFP transgene. J Neurosci 21 (2001) 3895-3903
88. 18F]-6-L-fluorodopa PET studies of graft and host dopaminergic function following fetal mesencephalic transplantation. Adv Neurol 60 (1993) 715-720
89. Schapira A.H. Science, medicine, and the future: Parkinson's disease. BMJ 318 (1999) 311-314
90. Schwarz J., Schwarz S.C., and Storch A. Developmental perspectives on human midbrain-derived neural stem cells. Neurodegener Dis 3 (2006) 45-49
91. Shim J.W., Park C.H., Bae Y.C., Bae J.Y., Chung S., Chang M.Y., et al. Generation of functional dopamine neurons from neural precursor cells isolated from the subventricular zone and white matter of the adult rat brain using Nurr1 overexpression. Stem Cells 25 (2007) 1252-1262
92. Skottman H., Dilber M.S., and Hovatta O. The derivation of clinical-grade human embryonic stem cell lines. FEBS Lett 580 (2006) 2875-2878
93. Sonntag K.C., Simantov R., Kim K.S., and Isacson O. Temporally induced Nurr1 can induce a non-neuronal dopaminergic cell type in embryonic stem cell differentiation. Eur J Neurosci 19 (2004) 1141-1152
94. Storch A., Paul G., Csete M., Boehm B.O., Carvey P.M., Kupsch A., et al. Long-term proliferation and dopaminergic differentiation of human mesencephalic neural precursor cells. Exp Neurol 170 (2001) 317-325
95. Storch A., Sabolek M., Milosevic J., Schwarz S.C., and Schwarz J. Midbrain-derived neural stem cells: from basic science to therapeutic approaches. Cell Tissue Res 318 (2004) 15-22
96. Stromberg I., Bygdeman M., Goldstein M., Seiger A., and Olson L. Human fetal substantia nigra grafted to the dopamine-denervated striatum of immunosuppressed rats: evidence for functional reinnervation. Neurosci Lett 71 (1986) 271-276
97. Studer L., Tabar V., and McKay R.D. Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats. Nat Neurosci 1 (1998) 290-295
98. Tatard V.M., D'Ippolito G., Diabira S., Valeyev A., Hackman J., McCarthy M., et al. Neurotrophin-directed differentiation of human adult marrow stromal cells to dopaminergic-like neurons. Bone 40 (2007) 360-373
99. Uc E.Y., and Follett K.A. Deep brain stimulation in movement disorders. Semin Neurol 27 (2007) 170-182
100. Ueno M., Matsumura M., Watanabe K., Nakamura T., Osakada F., Takahashi M., et al. Neural conversion of ES cells by an inductive activity on human amniotic membrane matrix. Proc Natl Acad Sci USA 103 (2006) 9554-9559
101. Wagers A.J., Sherwood R.I., Christensen J.L., and Weissman I.L. Little evidence for developmental plasticity of adult hematopoietic stem cells. Science 297 (2002) 2256-2259
102. Wagner J., Akerud P., Castro D.S., Holm P.C., Canals J.M., Snyder E.Y., et al. Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by type 1 astrocytes. Nat Biotechnol 17 (1999) 653-659
103. Wenning G.K., Odin P., Morrish P., Rehncrona S., Widner H., Brundin P., et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol 42 (1997) 95-107
104. Winkler C., Kirik D., and Bjorklund A. Cell transplantation in Parkinson's disease: how can we make it work?. Trends Neurosci 28 (2005) 86-92
105. Yurek D.M., and Fletcher-Turner A. Comparison of embryonic stem cell-derived dopamine neuron grafts and fetal ventral mesencephalic tissue grafts: morphology and function. Cell Transplant 13 (2004) 295-306
106. Zhang S.C., Wernig M., Duncan I.D., Brustle O., and Thomson J.A. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat Biotechnol 19 (2001) 1129-1133
107. Zhao L.X., Zhang J., Cao F., Meng L., Wang D.M., Li Y.H., et al. Modification of the brain-derived neurotrophic factor gene: a portal to transform mesenchymal stem cells into advantageous engineering cells for neuroregeneration and neuroprotection. Exp Neurol 190 (2004) 396-406